Pharma

Your Article Summary

See Latest Articles

ACTEMRA inhibits progression of joint destruction in RA patients by over 80% compared to methotrexate alone
Chugai Pharmaceutical Co., 11/04/09

Two–year data from the LITHE study, being presented at the American College of Rheumatology, show that, with long–term use, patients with rheumatoid arthritis treated with ACTEMRA (tocilizumab, known as RoACTEMRA within the EU) plus methotrexate (MTX) suffered 81% less damage to their joints compared to those treated with MTX, the current standard therapy, alone.

Today in Research & Development...keeping you current

Receive free subspecialty "5-minute updates" via email

Novartis inaugurates large-scale US based cell-culture influenza vaccine manufacturing facility
Novartis, 11/25/09

Bayer CropScience signs Agreement with GVK Biosciences on early-stage research projects
BayNews International, 11/25/09

Reports Rate Ambulatory EHR Software
HealthDataManagement, 11/25/09

 See all of Research & Development